Drug intelligence / Profile preview

Brainvac

Development stage: Preclinical
Lead developer: Innovita Research
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Brainvac is a preclinical-stage cell-based cancer vaccine being developed by Innovita Research for the treatment of brain cancer. As a cell therapy, it is designed to stimulate the patient's immune system to recognize and eliminate malignant brain tumor cells. The program is part of Innovita Research's pipeline of cell-based products and is currently undergoing preclinical evaluation to establish safety and efficacy profiles for neuro-oncology indications.

Brand names: Brainvac

Beyond the preview

Go deeper on Brainvac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brainvac.

Explore the full profile